trastuzumab derxutecan

Phase 2

UUNICANCER

trastuzumab derxutecan is one of 7 therapeutic programs targeting Breast Cancer Metastatic. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Breast Cancer MetastaticRecruiting

Breast Cancer MetastaticPhase 2

Recruiting

Competition

Competitive Landscape

6 competitors in Breast Cancer Metastatic

#DrugCompanyPhaseTrials

Herceptin

Roche

Phase 2

3 2

Trastuzumab Deruxtecan

AstraZeneca

Phase 2

1 3

Orserdu

SStemline Therapeutics, Inc.

Phase 1

1 4

Lynparza

AstraZeneca

Preclinical

1 5

Patritumab Deruxtecan

Merck & Co.

Preclinical

1 6

trastuzumab derxutecan

UUNICANCER

Phase 2

1 7

DC1 Vaccine

HH. Lee Moffitt Cancer Center and Research Institute

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Recruiting

Breast Cancer Metastatic

NCT06680596

Clinical

Trials by Indication[1]

Breast Cancer Metastatic1 trial

A ctDNA Screening Program in Patients With HR+, HER2 Low Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor Followed by a Single Arm Phase II Trial of Trastuzumab-deruxtecan in Patients With Persistent ctDNA After 1 Month of Treatment With Endocrine Therapy Combined With CDK4/6 Inhibitor

Recruiting·UUNICANCER·Phase 2·NCT06680596·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for trastuzumab derxutecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for trastuzumab derxutecan. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — UNICANCER company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: UUNICANCER

trastuzumab derxutecan

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Breast Cancer Metastatic1 trial

References

Drug Info

Quick Facts

Related News